Clinical trial
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT02922764
Study timeline
Study start (actual)2016-11-01Date precision: day
Registry last updated2025-03-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Endometrial Cancerunresolved
Endometrial Cancer Recurrentunresolved
Lung Cancer Recurrentunresolved
Lung Cancerunresolved
Non-small Cell Lung Cancer Metastaticunresolved
Non-small Cell Carcinomaunresolved
Interventions
RGX-104DRUG
IpilimumabDRUG · verified · RxNorm: ipilimumab
DocetaxelDRUG · verified · RxNorm: docetaxel
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
CarboplatinDRUG · verified · RxNorm: carboplatin
PemetrexedDRUG · verified · RxNorm: pemetrexed
Sponsors & collaborators
Inspirna, Inc.lead sponsor
Mapped research locations
PhiladelphiaPennsylvania, United States2DenverColorado, United States2New YorkNew York, United States1Los AngelesCalifornia, United States1NashvilleTennessee, United States1PortlandOregon, United States1AuroraColorado, United States1Oklahoma CityOklahoma, United States1TucsonArizona, United States1New OrleansLouisiana, United States1LouisvilleKentucky, United States1FairfaxVirginia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02922764 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.